Anti-inflammatory activity of Arnica montana 6cH: preclinical study in animals.
The anti-inflammatory effect of Arnica montana 6cH was evaluated using acute and chronic inflammation models. In the acute, model, carrageenin-induced rat paw oedema, the group treated with Arnica montana 6cH showed 30% inhibition compared to control (P < 0.05). Treatment with Arnica 6cH, 30 min prior to carrageenin, did not produce any inhibition of the inflammatory process. In the chronic model, Nystatin-induced oedema, the group treated 3 days previously with Arnica montana 6cH had reduced inflammation 6 h after the inflammatory agent was applied (P < 0.05). When treatment was given 6 h after Nystatin treatment, there was no significant inhibitory effect. In a model based on histamine-induced increase of vascular permeability, pretreatment with Arnica montana 6cH blocked the action of histamine in increasing vascular permeability.
Macêdo
S B
SB
Faculdade de Odontologia, Pontificia Universidade Católica de Brasília, Brasília, Brazil.
Ferreira
L R
LR
Perazzo
F F
FF
Carvalho
J C
JC
D000208:Acute Disease; D000704:Analysis of Variance; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D018650:Arnica; D002351:Carrageenan; D002908:Chronic Disease; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D005534:Foot Diseases / Q000139:chemically induced / Q000188:drug therapy*; D006097:Granulation Tissue / Q000187:drug effects; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D009761:Nystatin; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D010936:Plant Extracts; D009761:Nystatin; D002351:Carrageenan